Vaccinia virus (VACV) gene F5L was recently identified as a determinant of plaque morphology that is truncated in Modified Vaccinia virus Ankara (MVA). Here we show that F5L also affects plaque morphology of the virulent VACV strain Western Reserve (WR) in some, but not all cell lines, and not via previously described mechanisms. Further, despite a reduction in plaque size for VACV WR lacking F5L there was no evidence of reduced virus replication or spread in vitro or in vivo. In vivo we examined two mouse models, each with more than one dose and measured signs of disease and virus burden. These data provide an initial characterization of VACV F5L in a virulent strain of VACV. Further they show the necessity of testing plaque phenotypes in more than one cell type and provide an example of a VACV gene required for normal plaque morphology but not replication and spread.
Introduction
Infection with vaccinia virus (VACV) disrupts numerous cellular pathways resulting in significant changes in cell morphology. Infection of confluent monolayers of many adherent cell lines with VACV results in the formation of large circular plaques due to a combination of cytopathic effects and migration of infected cells. Three groups of poxvirus genes affect plaque formation. Firstly the many poxvirus genes that are essential for virus replication are therefore required for plaque formation. Secondly, plaque formation is also reliant on spread of infectious extracellular virions (EV) mediated by actin tails. Therefore, loss of proteins involved either in morphogenesis or intracellular transport of wrapped virions (WV), or actin tail formation itself dramatically reduce plaque size despite production of high levels of mature virions (MV). A third group of genes are required for normal plaque morphology and size but less strongly affect virus output in vitro.
Analysis of members of this third group of genes has led to mechanistic insight into cytoskeletal rearrangements required for cell migration (F11L) and attachment to the extracellular matrix (C2L and A55R) (Pires de Miranda et al., 2003; Beard, Froggatt, and Smith, 2006; Valderrama et al., 2006; Morales et al., 2008; Cordeiro et al., 2009; Handa et al., 2013) .
VACV mutants with reduced plaque size or altered plaque morphology typically show altered virulence. Examples include VACV strain Western Reserve (WR) C16 and B14 (VACWR010/209 and VACWR196 respectively) both of which encode functions required for normal plaque size and for virulence (Chen, Jacobs, and Smith, 2006; Chen et al., 2008; Fahy et al., 2008) . Likewise, VACVWR with deletions of BTB/kelch proteins, C2 or A55, form wild type sized plaques with indistinct borders and cause altered lesions following intradermal infection of mice (Pires de Miranda et al., 2003; Beard, Froggatt, and Smith, 2006) . Beyond VACV, plaque size is positively correlated with case fatality rates for variola virus isolates within the same clade (Olson et al., 2009 ). Data such as these have led to a conventional view that changes to plaque morphology will be mirrored by in vivo changes to virus replication, spread and/or virulence.
We have recently identified F5L as another VACV gene that influences plaque morphology and spread during a study based on strain Modified Vaccinia virus Ankara (MVA) (Dobson and Tscharke, 2013) . MVA fails to replicate on most mammalian cell lines (Carroll and Moss, 1997; Drexler et al., 1998) , however using a marker rescue approach, Wyatt et al (1998) generated a set of recombinant MVAs (rescued MVAs) with improved replication on a range of mammalian cells.
We identified F5L, which is truncated in MVA but repaired in some of the rescued viruses, as a gene responsible for significant differences in plaque morphology across this set of rescued MVA strains (Dobson and Tscharke, 2013) . Further experiments found that while repair of F5 was associated with significant changes in plaque morphology it had no discernible effect on replication in vitro (Dobson and Tscharke, 2013) . F5L remains poorly characterized, but an early description of the VACV HindIII F region and the most accurate VACV-genome wide transcriptomic study found that it is expressed early after infection (Roseman and Slabaugh, 1990; Yang et al., 2010) .
F5 is not a component of mature virions (MV) (Chung et al., 2006; Yoder et al., 2006; Resch et al., 2007; Manes et al., 2008) and a large yeast-two-hybrid study found no interactions between F5 and other VACV proteins (McCraith et al., 2000) .
It was possible that the role found for F5 in the context of MVA was influenced by one or more of the many other genetic changes in MVA compared to most virulent VACV strains. Further, studies of virulence based on viruses with the MVA genetic background will be complicated by the loss of many virulence functions, some known and others yet to be defined (Blanchard et al., 1998) .
Indeed a recent report demonstrated that the rescued MVAs were highly attenuated and the rescued strain with the largest plaque was no more virulent than MVA in an intranasal infection model, even in immunocompromised mice (Melamed et al., 2013) . To address these issues, we explored the function of F5L in VACVWR. In this virulent VACV strain, F5 is required for normal plaque size and morphology in multiple cell lines, but was not required for replication or spread in any cells in vitro, nor for virulence in vivo.
Results
Conservation of F5 across the poxviruses and similarity to known proteins F5L (also annotated as VACWR044) encodes a 322 aa protein in VACVWR. F5 contains a predicted signal sequence, with a cleavage site between aa 20 and 21 (Signal P 3.0 (Bendtsen et al., 2004) ) and a putative transmembrane domain at the carboxyl-terminus (aa 287-311) (TMHMM (Krogh et al., 2001) ). Orthologs are found in all members of the orthopoxvirus genus for which genome sequence is available except ectromelia virus (Viral Orthologous Clusters, (Upton et al., 2003) ). The taterapoxvirus homolog is truncated to 193 aa and therefore lacks the putative transmembrane domain (GenBank Accession number NC_008291). No significant homologs are found outside the genus (BLASTp, E value <0.001). Beyond the poxviruses, the amino terminus of F5 contains a region with similarity to immunoglobulin V-set domain containing proteins, but this does not reach the significance threshold (E value=0.00036) (Pfam (Finn et al., 2010) ). Variation exists amongst F5L homologs from various strains of VACV (Fig. S1 ). For example, F5L from the VACV strain referred to as Ankara, used to rescue MVA for growth on BS-C-1 cells (Wyatt et al., 1998 ) and for our description of a role for F5 in the context of MVA (Dobson and Tscharke, 2013) , encodes a 321 amino acid protein due to a 3 bp deletion. In addition to this difference, ten nucleotide substitutions are present in Ankara F5L compared with VACVWR, resulting in four amino acid changes.
Deletion of F5L affects plaque morphology but not replication of VACVWR
A VACVWR strain with 86% of the F5L ORF deleted (VACVWRΔF5L) and a revertant (VACVWRF5Lrev) were made, demonstrating that F5 is non-essential for VACVWR growth in culture. However, plaques formed by VACVWRΔF5L were approximately 30% smaller than the parent or VACVWRF5Lrev on BS-C-1 cells. Cell clearance from the center of plaques was reduced and the distinctive halo of contracted cells that usually surround VACV plaques (Cordeiro et al., 2009 ) was absent ( Fig. 1a-d) . Further, live microscopy showed that the expansion rate of plaques was slower in the absence of F5 (Fig. 1c) . VACVWRΔF5L also formed smaller plaques on RK13, IEC-6, and 293A cells (Fig. 1b,e,f) . By contrast, we observed no difference in plaques formed on primary human foreskin fibroblasts, BHK-21 or the murine cell line NIH/3T3 (Fig. 1b , and data not shown).
To determine whether loss of F5 affected virus replication, a high multiplicity (m.o.i. = 5) growth experiment was done (Fig. 2a) . This found no decrease in replication associated with the loss of F5. We then used multiple-step experiments (m.o.i.=0.01) to measure replication and spread.
These found that deletion of F5L had no effect on either cell associated, or supernatant virus yield in BS-C-1 (Fig. 2b) or primary human foreskin fibroblasts (HFF) (data not shown). To probe replication and spread more stringently, inocula were reduced to approximately 50 p.f.u. in a 9.5 cm 2 culture of BS-C-1, so that spread would not be inhibited by a lack of infectable cells. Even in this experiment with six replicates, no statistically significant difference in virus output per plaque was across the parent, VACVWRΔF5Land VACVWRF5Lrev or between any pair of viruses at 72 hours post infection (h.p.i.) (Fig. 2c ). This last experiment was repeated and again no significant differences were found. Taken together, these experiments suggest that F5 has no discernable role in VACVWR replication or spread in in vitro culture, even on a cell line where it is required for normal plaque morphology.
Localization of the F5 protein in infected cells
In order to test the predicted cell membrane localization of F5 we produced VACVWR/F5LGFP in which the native F5 was replaced with an F5-eGFP fusion. This virus had a plaque phenotype similar to VACVWR on BS-C-1 cells (Fig. S2) , demonstrating that F5 function is intact in this virus.
There was diffuse fluorescence in cells infected with VACVWR/F5LGFP at several times after infection up to 8 h.p.i., but across multiple images we were unable to determine the localization with any certainty. The only common pattern that was evident across all images emerged from 6-8 h.p.i. and was an enrichment of eGFP at the periphery of the cell where thin cytoplasmic extensions are evident. This localization was restricted to regions in contact with neighboring cells, suggesting cell-cell contact might stabilize or recruit F5 (Fig. 3 ). This pattern of staining was not seen in cells infected by VACVWR expressing eGFP not fused to F5L, but was confirmed for F5-eGFP by total internal reflection fluorescence (TIRF) microscopy (not shown). To further define the location of F5-eGFP fluorescence, cells were stained for actin (phalloidin and cortactin), the cell-tocell junction marker β-catenin, or phosphotyrosine as a marker of focal adhesions. In each case projections marked with eGFP were noted, but these failed to co-localize with any of the host cell markers (Fig.3) . Finally, F5-eGFP did not colocalize with B5, a marker for enveloped virus (EV) or the virus factory, as shown by the DNA stain DAPI, where intracellular mature virus is assembled ( Fig. 3 row 3 and other rows respectively).
F5L is not required for actin tail formation, Ca 2+ independent cell adhesion or cell migration
Deletion of viral genes has identified three mechanisms associated with alterations in VACV plaque size and appearance which are not always matched by a measureable reduction in virus yield: 1) ability to make actin tails, 2) loss of adhesion of infected cells in the absence of Ca 2+ and
3) altered cell migration of infected cells. We considered whether deletion of F5 might act by these mechanisms, addressing each in turn below.
1) VACV morphogenesis is complicated and several forms of infectious virus are made. The form of virus implicated in virus spread in vivo is wrapped with an additional membrane (EV) and is able to be released from infected cells, or propelled into a neighboring cell by an actin tail (Roberts and Smith, 2008; Welch and Way, 2013) . Loss of certain proteins incorporated into the outer membrane of EV dramatically reduces plaque size either as a result of decreased EV production, reduced infectivity of the virus released, or decreased production of actin tails (Blasco and Moss, 1991; Duncan and Smith, 1992; Engelstad and Smith, 1993; Wolffe, Isaacs, and Moss, 1993; McIntosh and Smith, 1996; Wolffe et al., 1997; Roper et al., 1998; Ward and Moss, 2001 ).
Likewise, viruses lacking other genes required for efficient assembly and transport of WV or for actin tail formation, have very small plaques (Rodriguez and Smith, 1990; Parkinson and Smith, 1994; Wolffe, Weisberg, and Moss, 1998; Zhang, Wilcock, and Smith, 2000; van Eijl et al., 2002; Domi, Weisberg, and Moss, 2008; Dodding et al., 2009; Morgan et al., 2010) . We noted that the effect of F5L on plaque size was not as strong as published reports for these genes. Furthermore, F5 appeared not to be required for EV production and release because similar amounts of virus were found in the supernatant of cells infected with VACVWRΔF5L, its parent and the revertant (Fig 2b) . When 'comet' plaque assays were done with liquid overlay so that secondary plaques can be formed by released EV , the morphology of the primary and small secondary plaques but not the extent of secondary plaque formation were dependent on F5 (data not shown). Finally, actin tails were observed directly for our viruses. As shown in figure 4a, no significant difference in actin tail length was found between VACVWRΔF5L and VACVWRF5Lrev (Fig. 4a) .
2) When Ca 2+ is depleted from the growth medium, uninfected BS-C-1 cells lose the ability to adhere to the extracellular matrix and round up, but this process is inhibited by VACV infection (Sanderson and Smith, 1998) . The A55 and C2 proteins of VACVWR are required for VACVinduced Ca 2+ -independent cell adhesion. Like F5L, deletion of C2L or A55R alters plaque morphology without substantially affecting in vitro replication and plaques formed by VACVWRΔF5L appeared similar to published images of the VACVWR mutants, vΔC2 and vΔA55, so we wondered if F5 was required for Ca 2+ -independent adhesion (Pires de Miranda et al., 2003; Beard, Froggatt, and Smith, 2006) . BS-C-1 cells were infected with VACVWR, VACVWRΔF5L, or VACVWRF5Lrev for 18 hours before Ca 2+ was sequestered by adding EDTA to the medium and then adhesion of cells was monitored over 20 min (Fig. 4b ). Uninfected cells rapidly lost adhesion and rounded up. By contrast, the majority of virus-infected cells remained strongly adherent and the absence of F5 had no effect on this Ca 2+ -independent adhesion.
3) VACV infection induces migration of cells and protein F11 is involved in the cytoskeletal rearrangements required for this motility (Valderrama et al., 2006; Morales et al., 2008; Cordeiro et al., 2009; Handa et al., 2013) . As a result, deletion of F11L from VACVWR reduces plaque size (Morales et al., 2008; Cordeiro et al., 2009; Handa et al., 2013) and cells infected with MVA, in which F11L is fragmented, do not migrate into a wound made in a monolayer of serum starved BS-C-1 cells (Valderrama et al., 2006; Zwilling et al., 2010) . Initial live microscopy suggested that F5
was not required for cell motility (not shown) but to test this more quantitatively we measured migration of BS-C-1 cells infected with VACVWRΔF5L, VACWRF5Lrev, or VACVWR using a scratch wound assay ( Next, a complementation assay was used in which F5L fused to GFP was expressed from a plasmid under its natural promoter in cells infected by VACVWR or VACVWRΔF5L to determine if any domains were dispensable for function. Similar complementation assays have been used by others, including for genes with VACV early promoters, even though the early transcription factors are thought to be mostly sequestered in the virus cores (Cochran, Mackett, and Moss, 1985; Valderrama et al., 2006) . The plasmid also encoded mCherry under the VACV strong synthetic promoter (pSS), which was brighter than F5-eGFP to more easily identify cells that received virus and the plasmid at low magnification. A plasmid containing F5-eGFP, but not the empty vector was able to rescue the plaque defect of VACVWRΔF5L on 293A cells demonstrating expression of functional F5 (Fig. 6b ). Next, we tested the ability of a set of plasmids expressing F5-eGFP with regions of F5 deleted to rescue the plaque defect of VACVWRΔF5L. The predicted features of F5 covered by these deletions were the signal sequence, the extracellular domains (broken into four segments) and the short cytoplasmic tail (Fig. 6c ). Of these constructs, only the cytoplasmic tail deletion was still able to rescue the plaque size of VACVWRΔF5L, but eGFP fluorescence was always seen ( Figure S3 ). These experiments suggest that the putative cytoplasmic tail is not required for the function of F5 in plaque morphology.
F5L does not affect VACV pathogenesis, replication or spread in mice
We examined the role of F5 in VACV virulence using two murine models of infection. (Fig. 7b) .
Second, the intranasal model of infection was used. Three experiments were done with a dose of 1×10 4 p.f.u. and there were no statistically significant differences in weight loss or number of mice that were euthanized due to loss of >30% of starting weight between VACVWRΔF5L and the control viruses (Fig 8a) . A lower dose of 1×10 3 p.f.u. was then used to tease out any small difference between viruses, but again no consistent phenotype was found for VACVWRΔF5L ( Fig.   8a ). Virus titers were measured at three, seven and 10 days after intranasal infection with 1×10 4 p.f.u. of VACVWR, or VACVWRF5Lrev, examining lungs, brain, spleen (Fig. 8b ), ovaries and liver (not shown). No significant difference in titer was found between the groups of mice for any organ at any time. Finally we tested several parameters of immunity in mice infected intranasally with VACVWRΔF5L and controls. There were no differences in: a) the total VACV-specific IgG response as measured by ELISA (Tscharke, Reading, and Smith, 2002) ; b) the memory CD8 + T cell response in the spleen as measured by production of IFN-γ after stimulation with VACV peptide epitopes ; c) infiltrates present in brochoalveolar lavage taken at various times after infection (data not shown).
Discussion
We demonstrate here that VACV gene F5L is a determinant of plaque morphology in VACVWR when grown on a subset of cell lines tested, but does not contribute to virus replication in vitro in these same cells or to pathogenesis in mice. Taken at face value, smaller plaques in the absence of F5 suggest that this protein is required for normal spread of virus. However, no detectable change to replication in vitro was found despite using very low input titers to maximize the influence of virus spread. In addition, there was no defect in the ability of VACVWRΔF5L to replicate at primary sites of infection in mice, as seen in skin and lungs after intradermal and intranasal infection respectively, nor was there a defect in virus dissemination. In the case of the intradermal infection the above held true where the inoculated dose was as low as 100 p.f.u. and virus growth exceeded five orders of magnitude in five days, a very robust test of replication in vivo. It remains possible that deletion of F5L is associated with a very subtle reduction in virus production or spread that was beyond our sensitivity to dissect, but it is unclear that such a small difference would be important for the outcome of infection. Another important point highlighted by this study is that the effects of virus genes on plaques can be cell type-specific. We observed no difference in plaque size or morphology between VACVWRΔF5L and the wild type VACVWR when grown on BHK-21 (hamster), NIH/3T3 (mouse), or HFF (human), in contrast to the clear and reproducible differences seen for BS-C-1 (African green monkey), RK13 (rabbit), IEC-6 (rat) and 293A (human) ( Fig.1 and 6b) . A range of VACV genes have been characterized as being required for normal plaque morphology but when deleted have a minor (less than 10-fold) or undetectable effect on virus yield in multiple step growth curves. These include A55R, C2L (indistinct borders on BS-C-1) (Pires de Miranda et al., 2003; Beard, Froggatt, and Smith, 2006) ; C11R (10-30% smaller plaques on BS-C-1) (Buller et al., 1988) , VACVWR010/209 (approximately 20-30% smaller plaques on BS-C-1 and RK13) (Fahy et al., 2008) , O1L (plaques approximately 50% smaller on 293A) (Schweneker et al., 2012) and VACWR196 (smaller plaques on BSC-1 (20%) and CV-1(40%)) (Chen, Jacobs, and Smith, 2006) .
However, in each case viruses lacking these genes had altered pathogenesis in at least one model of infection in mice. In contrast for F5, over a total of six experiments across two models, no consistent role in virulence was observed, nor could an influence of this protein be found on three parameters of the immune response. The only other VACV protein associated with a plaque phenotype and not virulence is another membrane associated protein, A38, but pathogenesis was only assessed in a single model (Parkinson, Sanderson, and Smith, 1995) . There are a range of other VACV genes for which deletion does not change pathogenesis in mice, for example A45R, B9R and B12R, but in these cases there is a similar lack of phenotype for the deletion virus in vitro (Banham and Smith, 1993; Almazan, Tscharke, and Smith, 2001; Price, Tscharke, and Smith, 2002; Tscharke, Reading, and Smith, 2002 ). An example of a VACV protein with a known function that fails to alter pathogenesis in well controlled studies in mice is B8. B8 binds IFNγ from many species, but not mice, explaining its lack of function in mouse models (Alcamí and Smith, 1995; Symons et al., 2002) . However, the B8R ortholog in the mouse-specific pathogen ectromelia virus does bind mouse IFNγ and deletion from this virus reduces virulence (Sakala et al., 2007) . We speculate that F5 may lack a binding partner in this species, in support of this we saw no plaque defect in the absence of F5 on mouse NIH/3T3 cells, although we did observe a difference on another rodent cell line, IEC-6. It is interesting to note that ectromelia virus, a the mouse-specific orthopoxvirus lacks an F5L homolog. However, at the same time a role for virulence in mice has been shown for VACV genes K7R and A40R that are fragmented and therfore also non-functional in ectromelia virus (Tscharke, Reading, and Smith, 2002; Benfield et al., 2013 In summary, we identify F5 as a determinant of plaque phenotype in a virulent strain of VACV and the data presented provide a foundation for further work on this previously uncharacterized protein.
Finally, our investigations of F5L are a reminder that small plaque phenotypes should be checked in multiple cell lines cannot always be assumed to be a correlate of virus replication and spread.
Methods

Cells and virus
All cells were maintained in Dulbecco's modified Eagle medium (DMEM; Gibco/Invitrogen) with Lglutamine and 10% FBS (D10), except for BHK-21 (Minimum Essential Medium (Gibco/Invitrogen) with L-glutamine and 10% FBS). Lipofectamine 2000 (Invitrogen) was used for all transfections.
VACV stocks were grown in BHK-21 in DMEM with L-glutamine and 2% FBS (D2) and purified by centrifugation through a 36% sucrose cushion. Virus titers were determined by plaque assay on
Plasmid construction
PCR was used to generate inserts for InFusion (Clontech) or conventional cloning. In descriptions below, PCR primers for a) InFusion contain 15 bp matching flanking vector sequence (underlined) or a neighboring insert (bold); b) conventional ligations include restriction enzyme sites (italics).
Generation of recombinant VACV
General strategy: All recombinant VACV were produced by infection of 293A cells with the appropriate parent virus (m.o.i.= 0.05) followed by transfection 1 hour later with 1 µg of plasmid DNA. After 2 hours at 37°C transfection media was replaced with 2 ml D2. Cells were harvested 2 days later. Plaque purification was carried out on BS-C-1 in phenol-red free D2-CMC. PCR screening and sequencing was used to confirm the correct modification had occurred and identify plaque picks free of parental virus. Two independent recombinant viruses were isolated from parallel infection/transfection experiments. 
Evaluation of VACV plaques
Plaque size: Confluent cell monolayers in six-well plates were infected with 50 p.f.u. virus. After 2 hours at 37°C, the inoculum was replaced with semisolid D2+0.4% (w/v) carboxy-methyl cellulose (D2-CMC). Cells were fixed and immunostained with anti-MVA antibody followed by an anti-rabbit secondary antibody conjugated to horseradish peroxidase (Staib, Drexler, and Sutter, 2004) . ) were calculated for each virus strain using Image J (v1.46j) (Rasband, 1997 (Rasband, -2012 .
Replication in vitro
Confluent monolayers in six-well plates were infected with either 1x10 4 p.f.u. (multiple step growth curve ; m.o.i.=0.01) or 5x10 6 p.f.u (single step growth curve ; m.o.i.=5) virus in 1 ml D2. After 1 hour at 37°C, unabsorbed virus was removed, cell monolayer washed once, and 2 ml fresh media added. 0h samples were harvested immediately after addition of fresh media. Further wells were harvested at the indicated time points. Cells were harvested into existing media, centrifuged at 931xg for 10 minutes to separate cell-associated and supernatant virus, which were titrated separately. To calculate mean virus output per plaque, 9.5 cm 2 wells of confluent BS-C-1 were infected with 500 µl of virus diluted to 1x10with 2 ml D2 without CMC (6 wells per virus), or D2-CMC (3 wells per virus). 72 h.p.i. wells without CMC were harvested and virus titrated. Wells with D2-CMC were stained with crystal violet and plaques counted.
Antibodies and fluorescent chemicals
Primary antibodies used for immunofluorescence assays were: anti-B5 (Schmelz et al., 1994) 
Wound healing assays
Confluent BS-C-1 cells on glass coverslips were serum starved in DMEM without FBS (D0) for 2 hours, then infected (m.o.i.= 5). 1 h.p.i., wounds were created with a yellow tip and cells were washed in PBS and rescued in D0. Cells were fixed at 24 h.p.i. with 3% PFA in CB for 10 min, stained with DAPI and Alexa Fluor 568-phalloidin and mounted (as described above). All wounds were imaged with an Olympus microscope BX51 (10x objective), and an average wound size was calculated for mock infected cells. The number of cells containing DAPI stained nuclei within each wound were counted.
Calcium independent cell adhesion
Extracellular calcium was depleted by addition of EDTA (Sanderson and Smith, 1998) . Confluent CAGTGTGCTGGAATTCTTACTTGTACAGCTCGTCCATG and F5LRrev, and cloned into pSSmCB linearized with EcoRI. From pSSmCB::F5LGFP five further plasmids were constructed by amplification of the whole plasmid using phosphorylated primers. Plasmids contained deletions of amino acids (aa) 2-17, 25-69, 75-144, 145-225, or 226-261 . A plasmid containing F5L-GFP with a deletion of aa 315-322 was produced by splice overlap PCR using:
CTCGCCCTTGCTCACTCTTTTGTACATCGATATCGC and F5LRrev, and EGFPstop and pGFP (external primers in bold), followed by cloning into pSSmCB linearized with EcoRI. 293A cells were infected with 50-100 p.f.u. of VACVWR or VACVWRΔF5L, then transfected 1 hour later with 2 µg of plasmid DNA. Transfection media replaced after 3.5 hours with phenol-red free D2-CMC. 48 h.p.i. fluorescent plaques were photographed.
Expression of F5 in uninfected cells
Full length (F5L) or truncated (F5L218) F5L, amplified from VACVWR DNA with:
CGCGGGCCCGGGATCAACATTTATTAAACCGCATCAAG and either F5full:
GGCGACCGGTGGATCGTTATCTATATGCCTGTACTTGGAT or F5218:
GGCGACCGGTGGATCTGGAAACAGATAACAAGAAAACTCGTC, were cloned into pEGFP-N1.
293A cells were transfected with 2 µg of pEGFP-N1, pEGFP-N1::F5L, or pEGFP-N1::F5L218. 3hr post transfection, media was replaced with D2 for uninfected wells or VACVWRΔF5L or MVA (m.o.i= 5). 1 h.p.i. inoculum was replaced with 2 ml / well phenol-red free D2. After overnight incubation at 37°C, cells in the media were collected, while attached cells were washed with PBS and then removed using trypsin. Pooled cells were washed once with PBS, fixed using 1% PFA, and washed. eGFP fluorescence was measured using an LSR II flow cytometer (BD Biosciences) and data analyzed using FlowJo software (Tree Star Inc.). For inhibition of intermediate and late
gene expression, overnight media contained 40 µg ml -1 AraC.
Mice and infections
Mice were housed and all experiments carried out in compliance with ethical requirements under approval from the Animal Ethics and Experimentation Committee (ANU). Specific pathogen-free, female BALB/c mice were obtained from ARC (Perth, Australia) or APF (Canberra, Australia). For pathogenesis experiments, 8 week old mice were anesthetized by inhalation of isofluorane (4% in medical-grade oxygen at 0.8 litres/min) and intradermally injected with 1x10 4 p.f.u. or 1x10 2 p.f.u. in 10 µl PBS in the left ear pinnae (Tscharke and Smith, 1999; Lin, Smith, and Tscharke, 2012) , or infected intranasally with 1x10 4 p.f.u. or 1x10 3 p.f.u. in a total of 20 µl of PBS (10 µl per naris). For the dermal model, lesion sizes were estimated daily as described previously (Tscharke and Smith, 1999; Lin, Smith, and Tscharke, 2012) . After intranasal infection mice were weighed daily and monitored for signs of infection. Severely ill mice (clinical score >6) or those that lost more than 30% of baseline body weight that did not have an improving clinical score were euthanized.
Titration of virus from organs
The infected ears of intradermally infected mice were collected on day 5 p.i.. Organs were collected from intranasally infected mice at days 3, 7 or 10 p.i.. Ears or organs were homogenized in D2. Homogenates were frozen and thawed three times and sonicated for 20 sec three times, before titration.
Statistical analysis
Statistical comparisons were done using Prism Software (version 5.01; GraphPad). 
Figure Legends
